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Transforming growth factor-b2 (TGF-b2) stimulates the
expression of pro-fibrotic connective tissue growth factor
(CTGF) during the course of renal disease. Because
sphingosine kinase-1 (SK-1) activity is also upregulated by
TGF-b, we studied its effect on CTGF expression and on the
development of renal fibrosis. When TGF-b2 was added to an
immortalized human podocyte cell line we found that it
activated the promoter of SK-1, resulting in upregulation of
its mRNA and protein expression. Further, depletion of SK-1
by small interfering RNA or its pharmacological inhibition led
to accelerated CTGF expression in the podocytes. Over-
expression of SK-1 reduced CTGF induction, an effect
mediated by intracellular sphingosine-1-phosphate. In vivo,
SK-1 expression was also increased in the podocytes of
kidney sections of patients with diabetic nephropathy when
compared to normal sections of kidney obtained from
patients with renal cancer. Similarly, in a mouse model of
streptozotocin-induced diabetic nephropathy, SK-1 and CTGF
were upregulated in podocytes. In SK-1 deficient mice,
exacerbation of disease was detected by increased
albuminuria and CTGF expression when compared to wild-
type mice. Thus, SK-1 activity has a protective role in the
fibrotic process and its deletion or inhibition aggravates
fibrotic disease.
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Glomerular visceral epithelial cells, also denoted as podo-
cytes, build regularly spaced, interdigitated foot processes
that form the filtration slit and are connected by a thin
membrane-like slit diaphragm that has an important role in
the regulation of glomerular ultrafiltration.1,2 Damage of
podocytes, which can be triggered by various factors,
including oxidative and inflammatory stress, regularly leads
to foot process effacement and results in a destruction of the
filtration barrier and uncontrolled loss of proteins into the
urinary space, which is a hallmark of many forms of kidney
diseases.1–4 It was suggested that proteinuria is a result of
sublytic complement C5b-9 attack on podocytes, which leads
to the induction of various genes involved in the production
of oxidants, proteases, and growth factors, including the
transforming growth factor-b (TGFb) and the connective
tissue growth factor (CTGF).5
TGFb has an important role in many cell types.6,7 It
initiates cellular signaling by binding to the TGFb-receptor
type II, which interacts with the TGFb receptor type I
(TGFbRI) and results in the activation of the kinase activity
of TGFbRI. In turn, Smad proteins are phosphorylated and
translocate to the nucleus to act as transcription factors.6,7 In
the kidney, TGFb has a key effect in the induction of renal
fibrosis.8–10 Not surprisingly, in this context, TGFb is the
best known stimulator of CTGF, which is considered to have
a crucial role in wound repair and fibrosis,11,12 and is also
significantly upregulated in the course of fibrotic renal
disease.13 CTGF is proposed to stimulate fibroblast prolifera-
tion, matrix production, and promote adhesion and migra-
tion of many cell types, although the detailed molecular
mechanisms remain to be deciphered.14–16
Sphingolipids are important structural components of cell
membrane, which may exert additional functions as signaling
molecules under various physiological and pathophysiologi-
cal conditions.17,18 Sphingosine-1-phosphate (S1P) repre-
sents one of these bioactive molecules generated from
sphingosine by the action of sphingosine kinases (SKs). S1P
is involved in the regulation of pleiotropic cell responses,
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such as cell proliferation and differentiation, survival, and
migration.17–19
Two subtypes of SK have been identified, SK-1 and SK-2,
which are both ubiquitously expressed20,21 but show
differential enzymatic characteristics in that SK-2 possesses
a broader substrate specificity than does SK-1.21 Total SK
activity is stimulated in many cell types by various growth
factors, and also by proinflammatory cytokines. Whereas the
mechanism of SK-1 activation includes phosphorylation
reactions, membrane translocation,22,23 and transcriptional
events,24–26 the mechanism of SK-2 activation is still unclear.
In this study, we show that, in human podocytes, TGFb2
not only induces the expression of profibrotic CTGF but also
upregulates SK-1 activity. Depletion or inhibition of SK-1
leads to a higher CTGF expression, whereas overexpression of
SK-1 causes a suppression of CTGF expression. This regu-
lation is also observed in a mouse model of streptozotocin
(STZ)-induced diabetic nephropathy, in which SK-1 and CTGF
were both upregulated in podocytes under disease conditions.
Strikingly, in SK-1-deficient mice, an even higher expression of
CTGF was detected when compared with wild-type mice and
this correlated with a deterioration of the disease.
RESULTS
TGFb2 upregulates SK-1 activity by stimulating its gene
transcription
Stimulation of human podocytes with TGFb2 led to a
concentration (Figure 1a) and time-dependent (Figure 1b)
increase of SK-1 protein expression, as detected by western
blot analysis. The effect persisted for at least 48 h (Figure 1b).
A similar effect on SK-1 protein expression was also observed
when using TGFb1 (Figure 1c). The increased SK-1 protein
expression correlated with an increased SK-1 activity (Figure
1d). To discriminate the activity of SK-1 from SK-2, the
composition of the in vitro kinase buffer was changed. In
buffer conditions, including 1M KCl, in which SK-1 activity
is inhibited by more than 90% but SK-2 is still active, only a
minor activity of SK-2 was observed (Figure 1d, triangles)
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Figure 1 | Effect of TGFb2 on sphingosine kinase-1 protein expression and activity in human podocytes. Podocytes were stimulated
for 24 h with the indicated concentrations of TGFb2 (a); or for the indicated time periods with either vehicle (b, open symbols) or 5 ng/ml of
TGFb2, (b, closed symbols); or for 24 h with 5 ng/ml of TGFb1 (c). Thereafter, cell lysates were processed for western blot analysis (a–c) using
specific antibodies against human SK-1 (a and c, insets, upper panels) at a dilution of 1:1000, or glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (a and c, insets, lower panels) at a dilution of 1:2000. Bands corresponding to SK-1a were densitometrically
evaluated and are expressed as percentage of control and means±s.d. (n¼ 3) (d). Cells were stimulated for the indicated time periods with
either vehicle (open symbols) or 5 ng/ml of TGFb2 (closed symbols). Thereafter, cell lysates were taken for in vitro SK-1 (circles) or SK-2 (triangles)
activity assays as described in the Materials and Methods. SK-1 activity in control samples was at 10,509 c.p.m./min/mg of protein; SK-2 activity in
control samples was at 695 c.p.m./min/mg of protein. Data are expressed as percentage of unstimulated controls of SK-1 activity and
means±s.d. (n¼ 3). *Po0.05, **Po0.01, ***Po0.001 were considered statistically significant when compared with vehicle-stimulated values.
858 Kidney International (2009) 76, 857–867
or ig ina l a r t i c l e S Ren et al.: SK-1 suppresses CTGF expression in podocytes
compared with SK-1 activity. This remaining SK-2 activity
was not significantly altered by TGFb treatment (Figure 1d).
The upregulation of SK-1 protein expression was due to
increased de-novo protein synthesis and gene transcription,
as the protein synthesis inhibitor, cycloheximide, and the
transcriptional inhibitor, actinomycin D, blocked TGFb-
triggered SK-1 activity (Figure 2) and SK-1 protein expres-
sion (Figure 2, inset). Previously, we had shown that phorbol
ester is also a potent inducer of SK-1 expression and activity
in human endothelial cells26 and mesangial cells.27 Moreover,
in podocytes, phorbol ester TPA (12-O-tetradecanoyl-
phorbol-13-acetate) upregulated SK-1 activity (Figure 3)
and expression (Figure 3, inset). Co-treatment of cells with
TPA plus TGFb led to an additive effect on SK-1 activity and
expression (Figure 3), suggesting that at least two indepen-
dent signaling pathways are involved in a maximal expres-
sional upregulation of SK-1.
Moreover, TGFb2 also upregulated SK-1, but not SK-2,
mRNA expression levels, as shown by quantitative PCR
analysis (Figure 4a). To determine whether the increased
SK-1 mRNA levels occurred by an increased promoter
activation,26,28 SK-1 promoter studies were performed by
using a luciferase-containing vector fused with a 2492 bp
fragment of the human SK-1a promoter. Transfection of
podocytes with this construct, followed by TGFb2 stimu-
lation, revealed a more than twofold enhancement of SK-1
promoter activity (Figure 4b, right panel). Sequence analysis
of the SK-1 promoter revealed a putative Smad-3 (1237 bp
to –1229 bp) and a putative Smad-4-binding site (1581 bp
to –1572 bp) (Figure 4b left panel). Both sites were mutated
by site-directed mutagenesis. However, only the Smad-4-
binding site turned out to be functional, as a mutation of this
site, but not of the Smad-3-binding site, resulted in a loss of
TGFb-triggered promoter activation (Figure 4b, right panel).
To elucidate the mechanism by which TGFb2 induces SK-1
expression, various inhibitors of protein kinase modules were
tested. The induction of SK-1 by TGFb2 required TGFb2
receptor type I, as in the presence of a TGF-b receptor type I
kinase inhibitor, the TGFb2-induced SK-1 protein expression
was completely abolished (Figure 5a). In contrast, neither the
classical MAPK/ERK cascade inhibitor U0126, the general
protein kinase C inhibitor Ro 318220, inhibitors of p38-
MAPK SB 203580, SB 202190, and PD 169316, nor the JNK
inhibitor SP 600125 attenuated SK-1 expression (Figure 5a).
Furthermore, depletion by small interfering RNA (siRNA) of
the co-regulatory Smad-4, a downstream member of the
TGFb signaling device, completely abrogated TGFb-triggered
SK-1 upregulation (Figure 5b).
Suppressive role of SK-1 on TGFb-induced CTGF expression
To determine whether the upregulation of SK-1 by TGFb2 has
functional consequences for podocytes, a well-established
TGFb-regulated target gene was investigated, that is, the
CTGF, which is considered an important factor in fibrotic cell
response.13,15,16
The protein expression and subsequent secretion of CTGF,
which was increased by TGFb (Figure 6a, open columns),
were negatively regulated by SK-1, as the depletion of SK-1 by
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Figure 2 | Effects of cycloheximide and actinomycin D on
TGFb2-induced SK-1 protein expression and activity in human
podocytes. Podocytes were pretreated for 30min using vehicle
(–), cycloheximide (CHX; 10mg/ml), or actinomycin D (Act D;
5 mg/ml) before stimulation for 24 h with vehicle (Co) or TGFb2
(5 ng/ml). Thereafter, cell lysates were processed for western blot
analysis of SK-1 (inset, upper panel) or GAPDH (inset, lower panel),
or were taken for an in vitro SK-1 activity assay as described in the
Materials and Methods. Data in the inset are representative of
three experiments. Results in the graph are expressed as % of
control values and means±s.d. (n¼ 3). ***Po0.001 was
considered statistically significant when compared with
vehicle-stimulated control values; xxxPo0.001 compared with
TGFb-stimulated values.
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Figure 3 | Effect of phorbol ester on TGFb-induced SK-1
protein expression and activity in human podocytes.
Confluent podocytes were treated for 24 h with either vehicle
(Co), 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (100 nM), TGFb2
(5 ng/ml), or TPA plus TGFb2 as indicated. Thereafter, cell lysates
were processed for western blot analysis of SK-1 (inset, upper
panel) or GAPDH (inset, lower panel), or taken for an in vitro SK-1
activity assay as described in the Materials and Methods. Data in
the inset are representative of three experiments. Results in the
graph are expressed as percentage of control values and
means±s.d. (n¼ 3). ***Po0.001 was considered statistically
significant when compared with vehicle-stimulated values;
xxxPo0.001 compared with TGFb-stimulated control values.
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siRNA led to an amplified expression and secretion of CTGF
protein under basal as well as under TGFb-stimulated
conditions (Figure 6a, closed columns). The transfection of
podocytes with siRNA completely reduced the high expres-
sion of SK-1 obtained by TGFb stimulation when compared
with scrambled siRNA transfection (Figure 6b).
To exclude the possibility that the effects observed by
siRNA transfection are due to unrelated off-target phenom-
ena, we additionally tested a recently developed specific SK-1
enzyme inhibitor, SKI II.29 As seen in Figure 7, CTGF protein
expression induced by TGFb was also enhanced in the
presence of increasing concentrations of the inhibitor.
Moreover, a stable overexpression of SK-1 in podocytes by
a lentiviral transduction method resulted in a massive
accumulation of SK-1a and SK-1b in the transduced cells
(Figure 8, upper panel). In these cells, the secreted CTGF was
hardly detectable (Figure 8, lower panel), which further
stresses the negative regulation of CTGF by SK-1.
In line with the negative effect of SK-1 on CTGF
expression, its product S1P should reduce CTGF expression.
To this end, cells were stimulated with exogenous S1P, which
acted through surface S1P-receptors. However, this regimen
rather stimulated CTGF expression, which was already
observed at early time points of 2 h and 4 h (Figure 9a),
consistent with previous reports in other cell types.30,31 After
24 h, CTGF expression was comparable between control- and
S1P-stimulated cells (Figure 9b). As an intracellular way of
action of S1P is also possible and has been proposed by
various groups, we tested the effect of caged S1P.32 This S1P
derivative does not bind to S1P-receptors but penetrates the
cells and, on illumination, the protective group is cleaved off
to generate ‘active’ S1P in the cytoplasm.32 Figure 9b shows
that increasing concentrations of intracellularly released S1P
indeed reduced CTGF expression.
SK-1 and CTGF are overexpressed in podocytes from diabetic
nephropathy patients
To determine whether SK-1 is expressed in vivo in human
podocytes, renal sections of healthy controls and of patients
with diabetic nephropathy, according to Mogensen,33,34 were
examined by immunohistochemical staining. SK-1 was
hardly stained in podocytes of healthy samples, but in
patients with diabetic nephropathy, staining was much
more pronounced (Figure 10, arrowhead). In addition, an
increased CTGF expression was detected in diabetic podo-
cytes (Figure 10, arrow), confirming our previous study in
which we showed a coexpression of CTGF and TGF-b in
podocytes of diabetic patients.35 Thus, it is conceivable that
m
R
N
A 
ex
pr
es
sio
n 
(%
 of
 co
ntr
ol)
GGCGAGACG
Smad4
Smad4
Smad4
Smad3
Smad3
Smad3
+1
SK1a
SK1a
SK1a
WT
ΔSmad-3
ΔSmad-4
AGCCA “ACT“G
AGCCA “GAC“G
GGCG “TTT“CG
GGCG “AGA“CG
–1572 –1237–2563 –1581 –1229 –71
–2563 –71
–2563 –71
AGCCAGACG
SK-1
***
***
SK-2
Co 1 ng/ml 5 ng/ml
TGFβ2
Co
Co
Co
TGFβ
TGFβ
TGFβ
#
**
0 50 100 150 200 250
300
200
100
0
Luciferase activity (% of WT control)
a
b
Figure 4 | Effect of TGFb2 on SK-1 mRNA expression and promoter activity in human podocytes. (a) Podocytes were stimulated for 4 h
with either vehicle (Co) or the indicated concentrations of TGFb2. Thereafter, RNA was extracted and used for quantitative PCR of SK-1
(closed columns) or SK-2 (open columns), as described in the Materials and Methods. Results are expressed as percentage of control values
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the generated mutants are shown (left panel). Podocytes were transfected with DNA containing the WT 2492 bp fragment, the Smad-3-
mutated fragment (DSmad-3), or the Smad-4-mutated fragment (DSmad-4), as described in the Materials and Methods. Cells were
stimulated for 24 h with either vehicle (Co) or 5 ng/ml of TGFb2 (right panel). The ratio between firefly and Renilla luciferase activities was
calculated. Results are expressed as percentage of WT control and means±s.d. (n¼ 3); **Po0.01, ***Po0.001, xPo0.05 were considered
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the crosstalk between TGF-b and SK-1 signaling regulates the
CTGF expression in podocytes, emphasizing the relevance of
our in vitro findings for the development of renal disease.
SK-1-deficient mice develop a more severe STZ-induced
nephropathy
In a further approach to address the function of SK-1 in
regulating CTGF expression in vivo, STZ-mediated type 1
diabetes was induced in (C57BL/6) SK-1þ /þ and SK-1/
mice. Diabetic mice of both genotypes developed hypergly-
cemia with increased kidney-to-body weight ratios at day 30
compared with nondiabetic mice, with no distinguishable
changes among the diabetic groups, irrespective of the SK-1
gene dose (Table 1). The only genotype-specific difference
observed as a sign of progressive nephropathy was a sustained
increase in albuminuria (Po0.05) at days 20 and 30 in
diabetic SK-1/ compared with SK-1þ /þ diabetic mice
(Figure 11a). In agreement with our findings in human
diabetic glomeruli, STZ-induced diabetes mellitus resulted in
an enhanced protein expression of SK-1 in glomeruli, most
likely located in podocytes and mesangial cells (Figure 11b,
immunostaining, 30 days), and in tubules (data not shown)
from SK-1þ /þ diabetic kidneys. This increment was further
confirmed by western blot for SK-1 in nondiabetic and
diabetic SK-1þ /þ kidneys (Figure 11c and d). The specificity
of SK-1-detection in mouse kidney homogenates by western
blotting was confirmed by a preincubation of anti-SK-1
antibody with recombinant mouse SK-1 (Figure 11c,
‘negative control’). Furthermore, by performing in situ
hybridization, we detected an increased glomerular (Figure
11e) and tubular (data not shown) expression of CTGF
mRNA in diabetic kidneys from mice of both genotypes.
However, SK-1 deficiency markedly enhanced CTGF mRNA
expression in podocytes, as shown by in situ hybridization
(Figure 11e) and its semi-quantification (Figure 11f).
DISCUSSION
In this study, we have shown that in vitro TGFb2 potently
upregulates SK-1 expression and activity in glomerular
podocytes. In vivo, SK-1 is highly upregulated in podocytes
of kidneys from diabetic nephropathy patients, as well as in
kidneys from mice with STZ-induced nephropathy. We show
for the first time that, mechanistically, TGFb upregulated SK-
1 expression by stimulating the SK-1 promoter activity
(Figure 4b). Promoter sequence analyses revealed two
putative Smad-binding elements, one Smad-3 and one
Smad-4-binding site (see Figure 4a). By site-directed
mutagenesis of these two sites, we identified the Smad-4-
binding site as a functional site responsible for the TGFb-
triggered effect. Previously, it was shown that Sp1 and AP-2
sites were involved in phorbol ester-induced SK-1 promoter
activation in the leukemia cell line, MEG-O1.36 In addition,
we recently identified a functional hypoxia-responsive
element that mediates hypoxia-triggered SK-1 upregulation
in human endothelial cells,37 and a STAT5-binding site that
mediates prolactin-triggered SK-1 upregulation in the human
breast cancer cell line, MCF7.28 All these data underline that
SK-1 activity is tightly regulated by transcriptional mechan-
isms. Obviously, the TGFb/Smad signaling cascade represents
one possible mode of upregulation of SK-1 expression and
activity, whereas phorbol ester-activated PKC signaling is a
further separate mode of SK-1 expression and activation. In
combination, TGFb plus phorbol ester exerted an additive
effect on SK-1, as one expects from independent signaling
pathways acting on the same cell response. Together, this
suggests that for a full persistent activation of SK-1,
activation of both the PKC and Smad signaling modules is
required. A similar upregulation of SK-1 mRNA and activity
by TGFb was also reported for dermal fibroblasts, although
the mechanism was not further addressed.38
In functional terms, our data show that the activation of
SK-1 by TGFb is involved in the regulation of the important
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Figure 5 | Effect of various kinase inhibitors or of Smad-4
depletion on SK-1 protein expression in human podocytes.
(a) Podocytes were pretreated for 30min using the indicated
concentrations (in mM) of TGFbRI inhibitor (TKI), U0126, Ro 318220
(Ro), SB 203580 (SB1), SB 202190 (SB2), PD 169316 (PD), or
SP600125 (SP) before stimulation with either vehicle (Co,) or
5 ng/ml of TGFb2. (b) Podocytes were transfected with vehicle
(Co), small interfering RNA (siRNA) for human Smad-4 (si), or a
scrambled siRNA (scr) as recommended by the manufacturer. At
48 h after transfection, cells were stimulated with either vehicle or
5 ng/ml of TGFb2 for 24 h. Thereafter, cells were processed for
western blot analysis of SK-1 (1:1000), Smad-4 (1:1000) (b, inset
upper panel), or glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (1:2000) (b, inset, lower panel). Bands corresponding to
SK-1a were densitometrically evaluated and are expressed as
percentage of control and means±s.d. (n¼ 3). ***Po0.001 was
considered statistically significant when compared with vehicle-
stimulated values; xxxPo0.001 compared with TGFb-stimulated
control values.
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profibrotic factor, CTGF. CTGF is upregulated in most
fibrotic diseases, including human crescentic glomerulone-
phritis39 and experimental proliferative glomerulonephritis.40
In view of these data, SK-1 may act as a brake in a fibrotic
event by impeding CTGF expression. This is further
supported by our in vivo model showing that SK-1-deficient
mice not only express higher amounts of CTGF but also
develop a more severe diabetic nephropathy when treated
with STZ and compared with SK-1 wild-type mice.
Most notably, we found that the suppressive effect of SK-1
is exclusively mediated by locally generated intracellular S1P,
and not by extracellular S1P acting through S1P-receptors. In
fact, extracellular S1P even has an opposite effect and can
increase CTGF expression and may thereby even worsen a
fibrotic process. The mechanisms by which intracellular S1P
suppresses CTGF protein expression remain unknown,
because the identity of intracellular S1P targets is still not
defined. Various studies have shown that intracellular S1P
triggers an intracellular Ca2þ mobilization, which occurs inde-
pendently of a phospholipase C/IP3-driven Ca
2þ release.41
Thus, it is tempting to speculate that Ca2þ channels are
directly affected by intracellular S1P.
Inhibition of SK-1 has been proposed as a useful approach
to treat tumor growth, as shown in a mouse xenograft
model.29,42 Additional in vivo effects of these SK-1 inhibitors
have not yet been addressed. Our data show that SK-1
inhibition also results in an increased CTGF expression in
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Figure 6 | Effect of SK-1 depletion by small interfering RNA (siRNA) on TGFb-induced connective tissue growth factor (CTGF) protein
expression in human podocytes. (a) Podocytes were transfected with either a scrambled siRNA () or siRNA for SK-1 (þ ) before
stimulation for 24 h with either vehicle (DMEM) or TGFb2 (5 ng/ml). Thereafter, supernatants were taken for protein precipitation using
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subjected to a western blot analysis using an antibody against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (inset, lower panel).
(b) Protein lysates of unstimulated untransfected cells (Co), TGFb-stimulated scrambled transfected (scr) or TGFb-stimulated SK-1-siRNA
transfected (siSK1) cells were analyzed by western blots for protein expression of SK-1 (upper panel) or GAPDH (lower panel). Bands
corresponding to CTGF were densitometrically evaluated and are depicted as bars. Results are expressed as percentage of control values
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connective tissue growth factor (CTGF) protein expression in
human podocytes. Podocytes were pretreated for 30min with
either vehicle () or the indicated concentrations of the SK-1
inhibitor (SKI II; in mM) before stimulation with TGFb2 (5 ng/ml;þ ) for
24h. Thereafter, supernatants were taken for protein precipitation
using trichloroacetic acid and for the determination of secreted
CTGF protein (upper panel) by western blot analysis using an
antibody against CTGF at a dilution of 1:1000. The corresponding
cell lysates were taken for GAPDH analysis (lower panel). Data are
representative of four experiments giving similar results.
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Figure 8 | Effect of SK-1 overexpression on connective tissue
growth factor (CTGF) protein expression in human podocytes.
Podocytes were taken either untransduced and stimulated for
24 h with TGFb2 (5 ng/ml) in the absence or presence of SKI II
(10mM) or transduced with a lentiviral construct containing
SK-1aþb. Thereafter, cell lysates were taken for determination of
SK-1 (upper panel) and GAPDH (glyceraldehyde-3-phosphate
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(supernat.) were taken for protein precipitation using
trichloroacetic acid and for the determination of secreted CTGF
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against SK-1 (dilution 1:2000, upper panel), GAPDH (dilution
1:3000, middle panel), and CTGF (dilution 1:1000, lower panel).
Data are representative of three experiments giving similar results.
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kidney cells and this could lead to adverse side effects when
using SK-1 inhibitors in vivo. However, it should be noted
that the relation of CTGF with tumor development and
growth is still controversial. On the one side, a reduced CTGF
expression was reported for various tumors, including lung
cancer,43 leading to speculations that CTGF could be a tumor
suppressor. Consistent with this idea, increased CTGF levels
were shown to inhibit the metastatic activity of human lung
cancer cells.44,45 Most recently, it was shown that CTGF
levels were decreased in Wilms tumor (nephroblastoma),46
and that recombinant CTGF inhibited the proliferation
of a Wilms tumor cell line. On the other side, CTGF was
proposed to promote angiogenesis47 and tumorigenesis of
prostate cancer cells.48 Moreover, blocking CTGF action by a
recently developed neutralizing antibody, FG-3019, inhibited
pancreatic tumor growth and metastasis.49,50 Overall, these
data raise the question whether inhibition of SK-1 could have
a beneficial or deteriorating effect on renal fibrotic diseases.
In this context, it has previously been reported that STZ-
induced diabetic nephropathy in rats correlated with an
accumulation of S1P in glomeruli isolated from kidney
cortex.51 Moreover, high glucose conditions led to an
increased SK-1 activity in endothelial cells52 and in vascular
smooth muscle cells,53 proposing a role for SK-1 in diabetic
vasculo- and nephropathies. However, these studies did not
address whether SK-1 positively promotes diabetic nephro-
pathy or whether SK-1 is induced as a rescue mechanism to
counter-regulate disease progression. Recently, Kono et al.54
reported that SK-1 is upregulated in fibrotic foci in a mouse
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Figure 9 | Effects of exogenously applied S1P and
intracellularly generated S1P on connective tissue growth
factor (CTGF) expression. (a) Podocytes were stimulated for
2 h and 4 h with either vehicle (Co) or 3 mM of exogenous S1P.
(b) Cells were stimulated for 24 h with either vehicle (Co), 3 mM of
exogenous S1P, or 3 mM and 10 mM of caged S1P (illuminated for
30 s at 360 nM and with a change of medium before stimulation).
Thereafter, supernatants were taken for protein precipitation
using trichloroacetic acid and for the determination of secreted
CTGF protein (upper panels) by western blot analysis using an
antibody against CTGF at a dilution of 1:1000. The corresponding
cell lysates were taken for GAPDH analysis (lower panels). Data are
representative of four independent experiments giving similar
results.
CTGF
SK-1
Control Diabetic
nephropathy Negative control
50 μm
100 μm
Figure 10 | Immunohistochemical staining of SK-1 in kidney sections from patients with diabetic nephropathy. Glomerular SK-1 and
connective tissue growth factor (CTGF) expression in normal human kidney (control, left panels) and in kidneys from patients with manifest
diabetic nephropathy (middle panels) were detected by immunohistochemical staining using an anti-SK-1 antibody as described in the
Materials and Methods. The arrowhead points to SK-1 expression and the arrow points to CTGF expression in podocytes. Renal sections
from patients with diabetic nephropathy were used as negative controls by omitting the primary antibody (right panels). Bars indicate
magnification.
Kidney International (2009) 76, 857–867 863
S Ren et al.: SK-1 suppresses CTGF expression in podocytes o r ig ina l a r t i c l e
model of pulmonary fibrosis, although no SK-1/ mice were
used in that study to prove the in vivo contribution of SK-1
to the disease. Our studies using SK-1/ mice now suggest
that SK-1 induced under disease conditions exerts a protective
function and its depletion results in a more severe kidney
disease.
In summary, our data have shown that in human
podocytes, TGFb potently upregulates SK-1 expression and
activity, which critically contributes to a negative regulation
of CTGF expression, which exerts a key effect in organ
fibrosis. Furthermore, the in vivo model of STZ-induced
diabetic nephropathy showed that SK-1 exerted a protective
function, as SK-1/ mice developed a more severe disease
that correlated with an enhanced CTGF expression. However,
this study leaves open tantalizing questions with regard to
extracellular and intracellular S1P and whether inhibition of
SK-1 in vivo is a good or bad effect. This thrilling question
definitely needs to be addressed in future studies.
MATERIALS AND METHODS
Chemicals
TGF-b was obtained from R&D Systems (Wiesbaden, Germany);
cycloheximide, actinomycin D, and STZ were purchased from
Sigma-Aldrich Fine Chemicals (Deisenhofen, Germany); and all
inhibitors were obtained from Merck Biosciences (Schwalbach,
Germany). The CTGF (L-20) antibody, GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) (V-18) antibody, and the human Smad-4
siRNA (sc-29484) were purchased from Santa Cruz Biotechnology
(Heidelberg, Germany); the SK-1-specific antibody was generated
and characterized as previously described.25,26
Cell culture
A human immortalized podocyte cell line was cultured as
described.55 Cells were normally cultured at 33 1C. For experiments,
cells were cultured at 37 1C for a further 10 days. These cells were
characterized by the expression of the podocyte-specific protein,
nephrin.1,55 For synchronization, cells were incubated for 16 h in
Dulbecco’s modified Eagle’s medium, including 0.1mg/ml of fatty
acid-free bovine serum albumin.
siRNA transfections
Gene silencing of human SK-1 was performed exactly as previously
described.26,28 Silencing efficiency was confirmed by western blot
analysis.
Quantitative PCR analysis
Real-time PCR was performed using a BioRad iQ-iCycler Detection
System (BioRad, Mu¨nchen, Germany). Primer sequences were as
follows: human GAPDH (accession number: NM_002046): forward:
GCTCTCTGCTCCTCCTGTTC; reverse: CGCCCAATACGACCAA
ATCC; human SK-1 (accession number: NM_021972): forward:
GGGCTTCATTGCTGATGTGGAC; reverse: TGCCTGCCATTACAA
CTGTCC; IQ5 Optical System Software (version 2.0, BioRad) was
used to analyze real-time and end point fluorescence.
Western blot analysis
Stimulated cells were homogenized in lysis buffer and processed as
previously described.25,26 Protein of 30 mg was separated on sodium
dodecyl sulfate polyacrylamide gel electrophoresis, transferred to
nitrocellulose membrane, and subjected to western blot analysis. To
prove that the anti-human SK-1 antibody also specifically
recognized mouse SK-1 in mouse kidney homogenates, the antibody
was preincubated with recombinant mouse SK-1a (SPHK1a,
Biomol, Hamburg, Germany) for 12 h at 4 1C before an overnight
incubation at 4 1C with the western blot of nondiabetic and diabetic
homogenates of SK-1þ /þ kidneys.
SK activity assay
In vitro kinase reactions were performed exactly as previously
described.26 For SK-1 activity, 0.5% Triton X100 was included to
block SK-2 activity.21 For SK-2 activity, 1M KCl was included to
block SK-1 activity.21
SK-1 promoter studies
A 2492 bp fragment of the human SK-1a promoter was cloned by
reverse transcriptase PCR using the following primers: forward with
an Nhe1 side: GCTAGCAGGTGCAGGACCCATCATTC; reverse with
a HindIII side: AAGCTTCCTGCCTTCAGCTCCTTATC. The pro-
moter fragments were fused into the pGL3 luciferase reporter gene-
containing vector (Promega, Mannheim, Germany). Cell transfec-
tions and reporter assays were performed exactly as described.26
Values for relative SK-1 promoter activities were calculated from the
ratio of firefly/Renilla luciferase activities.
Promoter mutations
All mutated constructs were generated using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) using the
following mutation primers: for pGL-hSK1a-DSmad3: forward:
GCCGCCTTCTAGCCAACTGCCTAGGACGAGCGGC (GAC to
ACT); for pGL-hSK1a-DSmad4: forward: TGGGCGGCGGGCGTTT
Table 1 | Effects of streptozotocin (STZ)-induced diabetes (day 30) on body weight, kidney weight, and blood glucose levels in
SK-1+/+ and SK-1/ mice
Nondiabetic (n=6) Diabetic (n=6)
SK-1+/+ SK-1/ SK-1+/+ SK-1/
Body weight, day 0 (g) 27.3±0.6 26.2±1.7 26.9±1.3 25.9±1.8
Body weight, day 30 (g) 28.1±0.1 27.4±1.5 23.3±2.1a 22.5±1.7b
Kidney weight (mg) 205±21 199±23 227±18a 261± 10b
(Kidney weight/body weight) 103 7.3±0.9 7.3±0.9 9.9±1.2a 11.7±0.7b
Blood glucose (mg per 100ml) 96±5 95±4 422±32a 426±36b
Data are given as means±s.d., Po0.05.
aFor diabetic SK-1+/+ versus nondiabetic SK-1+/+ mice.
bFor diabetic SK-1/ versus nondiabetic SK-1/ mice.
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CGCCCCGGCCTGGAGA (GAG to TTT). The mutated sites were
verified by sequencing.
Tissues for histological investigations
For controls, tumor-free kidney samples were obtained from six
patients undergoing nephrectomy for renal carcinoma. Diabetic
changes were examined in tissues from two kidney biopsies with no
evidence of malignancy and in six tumor-free samples from
carcinoma kidneys from patients with manifest diabetic nephro-
pathy. The clinical data of these patients have been described
previously.35,56 The study was approved by the Ethical Committee of
the Medical Faculty, University of Muenster.35
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Figure 11 | Effect of SK-1 deficiency on albuminuria and connective tissue growth factor (CTGF) expression in streptozotocin-
induced diabetes mellitus in mice. (a) Urinary albumin excretion normalized to creatinine levels in the urine from nondiabetic and diabetic
SK-1þ /þ and SK-1/ mice before induction of diabetes mellitus (day 0), as well as 10, 20, and 30 days after the last streptozotocin (STZ)
injection. The asterisk between bars indicates statistical differences between diabetic SK-1þ /þ and SK-1/ mice, Po0.05, n¼ 6.
(b) Immunostaining (brown color) for SK-1 in glomeruli of nondiabetic and diabetic SK-1þ /þ kidneys after 30 days of STZ diabetes. Renal
sections from diabetic SK-1þ /þ mice were used as negative controls by omitting the primary antibody. Bars indicate magnification.
(c) Western blot and (d) quantification of SK-1 (45 kDa plus 32 kDa) and b-tubulin in homogenates of diabetic kidneys from SK-1þ /þ mice at
day 30 of diabetes. Anti-SK-1 antibody preincubated with recombinant mouse SK-1 was used for western blotting as a negative control,
indicating specificity of antibody detection (c). The asterisk between bars indicates statistical differences between diabetic and nondiabetic
SK-1þ /þ kidneys, Po0.05, n¼ 3 (d). Data are given as means±s.d. of the ratios of optical density for SK-1 (45 kDa plus 32 kDa) to b-tubulin.
(e) In situ hybridization of CTGF in glomeruli of nondiabetic and diabetic SK-1þ /þ and SK-1/ kidneys after 30 days of STZ diabetes and
(f) its semi-quantification expressed as the ratio (%) of the glomerular CTGF mRNA-positive area to the whole glomerular area from 10
randomly selected high-power fields. Arrows indicate expression of CTGF in podocytes. Bars indicate magnification. The asterisk between
bars indicates statistical differences between diabetic and nondiabetic SK-1þ /þ kidneys, *Po0.05, n¼ 5.
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Tissue samples were fixed and prepared as previously de-
scribed.56 Paraffin sections (2–6 mm) were stained using periodic
acid–Schiff reagent to ascertain the absence of tumor infiltration and
were processed for immunohistochemistry using a rabbit anti-
human SK-1 antibody at a dilution of 1:500 and a secondary alkaline
phosphatase-coupled anti-rabbit antibody. Counterstaining was
performed using Mayer’s hemalaun. For mouse tissue, serial sections
(3–5 mm) of paraffin-embedded mouse kidney samples were used.
Counterstaining was performed using methyl green. The specificity
of staining was ascertained using negative controls by omitting the
primary antibody and by using non-immune serum ‘unspecific’ IgG.
In situ hybridization in mouse kidney
A DNA probe comprising nucleotides 1–492 of mouse CTGF cDNA
was used for in situ hybridization of formaldehyde-fixed and
RNAse-free paraffin-embedded kidney sections as described pre-
viously.56 To semi-quantify the expression of CTGF, 10 randomly
selected nonoverlapping fields of the renal cortex were examined
under high-power-field magnification and the ratio (%) of the
glomerular CTGF-mRNA-positive area to the whole glomerular area
was determined using the Soft Imaging System (Olympus, Tokyo,
Japan). Mean values of at least five kidneys per group were averaged.
Animal experiments
All animal experiments were conducted in accordance with the
German Animal Protection Law and were approved by the Ethics
Review Committee of the District Governments of Muenster and
Darmstadt, Germany. To induce type-1 diabetes, 2-month-old male
SK-1þ /þ (C57BL/6) and SK-1/ mice57 were intraperitoneally
injected with STZ (45mg/kg of body weight) dissolved in 100mM
sodium citrate buffer (pH 4.5) for four consecutive days. Control
animals were injected with citrate buffer. Mice that had developed
glycosuria received a subcutaneous insulin implant (Linplant)
(Linshin, Ontario, Canada) to prevent ketoacidosis. Blood glucose levels
were controlled every 10 days (Haemo-Glukotest; Roche Diagnostics,
Mannheim, Germany). Urinary glucose and ketones were measured
using reagent strips (Keto-Diastix Reagent Strips, Bayer Vital,
Leverkusen, Germany). Urinary creatinine excretion was determined
with the Creatinine Assay Kit (NatuTec, Frankfurt/Main, Germany), and
the Albuwell M ELISA Kit (Exocell, Philadelphia, PA, USA) was used for
quantification of urinary albumin excretion. Kidneys (n¼ 6 per group)
were harvested and analyzed 30 days after induction of diabetes.
Statistical analysis
Statistical analysis was performed using one-way analysis of
variance, followed by Bonferroni’s post hoc test for multiple
comparisons.
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